Under the expanded agreement, Sequenom will include its Center for Molecular Medicine’s (CMM) MaterniT21 PLUS test, in the PHCS and MultiPlan networks, to detect certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal abnormalities.

Sequenom chairman and CEO Harry Hixson said the company is pleased to extend its relationship with MultiPlan, giving their clients’ members and their network of participating providers access to the MaterniT21 PLUS test.

"Of the many important decisions to make in a high-risk pregnancy, the coverage of a valuable noninvasive prenatal test will be a relief to many expectant families," Hixson added.

The MaterniT21 PLUS test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation.